Det firma, der fremstiller Velcade, skal gennemføre yderligere undersøgelser, som især fokuserer på fordelingen af Velcade i kroppen (især efter gentagne doser) og på risikoen for, at patienterne udvikler amyloidose (ophobning i kroppen af en type protein, der kaldes amyloid), eller at amyloidosen forværres.
The company that makes Velcade will carry out further studies looking in particular at the distribution of Velcade in the body (especially after repeated doses), and at the risk of patients developing amyloidosis (a build-up of a type of protein called amyloid in the body) or of amyloidosis getting worse.